Hereditary Mixed Polyposis Syndrome (HMPS) Cell Models for Research

Hereditary Mixed Polyposis Syndrome (HMPS) is a rare autosomal dominant disorder characterized by multiple mixed polyps in the colorectum, with a high risk of progression to colorectal cancer (CRC). The exact global incidence is not well-defined due to underdiagnosis and variable penetrance; however, it is estimated to account for less than 1% of all hereditary CRC syndromes (WHO, 2023). HMPS typically presents in the second to fourth decade of life, with polyps that can be adenomatous, hyperplastic, or serrated. The lifetime risk of CRC in affected individuals is approximately 30-50% (NCI, 2023). The 5-year survival for localized CRC is about 90%, but drops to 14% for distant stage disease (NCI SEER, 2023). Key risk factors include a family history of polyposis and specific germline mutations in GREM1 or BMPR1A. The clinical impact is significant due to the need for frequent surveillance and prophylactic surgery, making early diagnosis and targeted therapies critical.

HMPS serves as an excellent model for studying colorectal tumorigenesis because it involves well-defined genetic drivers that activate the BMP/Wnt signaling pathways. The disease provides a clear genotype-phenotype correlation, allowing researchers to dissect the molecular mechanisms of polyp formation and progression. Public datasets, such as TCGA and COSMIC, include HMPS-related mutations (e.g., GREM1 duplications, BMPR1A loss) that can be used for bioinformatic analysis. Open questions include the role of stromal-epithelial interactions and the potential for targeted therapies against BMP or Wnt pathways. Gene-edited cell models are invaluable for functional validation of these mutations.

HMPS is driven by dysregulation of the BMP (Bone Morphogenetic Protein) and Wnt signaling pathways. The major carcinogenic pathways include:

• • BMP signaling pathway:

1. Ligand (e.g., BMP2/4) binds to BMPR1A/BMPR2 receptor complex.

2. Phosphorylation of SMAD1/5/8.

3. Complex with SMAD4 and translocation to nucleus.

4. Regulation of target genes involved in cell proliferation and differentiation.

5. In HMPS, loss-of-function mutations in BMPR1A or overexpression of GREM1 (a BMP antagonist) lead to reduced BMP signaling, promoting stem cell expansion and polyp formation.

• • Wnt signaling pathway:

1. Wnt ligands bind to Frizzled receptors and LRP5/6 co-receptors.

2. Disruption of the APC destruction complex.

3. Stabilization and nuclear translocation of beta-catenin.

4. Activation of TCF/LEF transcription factors, driving proliferation.

5. In HMPS, GREM1 overexpression also enhances Wnt signaling indirectly by maintaining stem cell niche, leading to crypt hyperplasia.

The following table summarizes the high-frequency genetic alterations in HMPS based on data from TCGA, COSMIC, and ClinVar (2023).

Note: Frequencies are approximate and derived from small cohort studies; HMPS is rare, so data are limited.

HMPS involves complex interplay between BMP and Wnt signaling, as well as cross-talk with other pathways. Key deregulated networks include:

• • BMP signaling network:
• • BMPR1A, BMPR2, SMAD1/5/8, SMAD4.
• • Antagonists: GREM1, NOGGIN, CHRD.
• • Downstream targets: ID1, ID3, CDKN2B.
• • Wnt signaling network:
• • Receptors: FZD, LRP5/6.
• • Core components: APC, AXIN1/2, GSK3B, CTNNB1.
• • Transcription factors: TCF7L2, LEF1.
• • Target genes: MYC, CCND1, LGR5.
• • MAPK pathway (often co-activated):
• • KRAS, BRAF, MEK1/2, ERK1/2.
• • PI3K/AKT pathway:
• • PIK3CA, PTEN, AKT1, MTOR.

These networks are interconnected; for example, BMP inhibition can lead to increased Wnt activity, and KRAS mutations can enhance both pathways. Gene-edited models targeting these nodes are crucial for understanding the signaling hierarchy.

Common cell lines used for HMPS research include colorectal cancer lines with relevant mutations. The table below lists key cell lines and their origins.

Organoids derived from HMPS patient tissues are also valuable, as they recapitulate the 3D architecture and stem cell niche. They can be genetically engineered using CRISPR to model GREM1 overexpression or BMPR1A loss, providing a more physiologically relevant platform for drug testing.

Animal models for HMPS include:

• • Patient-derived xenografts (PDX):
• • Implantation of HMPS tumor or polyp tissue into immunodeficient mice.
• • Preserves tumor heterogeneity and stromal interactions.
• • Useful for drug efficacy testing.
• • Genetically engineered mouse models (GEMM):
• • BMPR1A conditional knockout mice (e.g., Villin-Cre; Bmpr1a fl/fl) develop intestinal polyposis.
• • GREM1 overexpression models (e.g., transgenic mice with GREM1 under intestinal promoter) show mixed polyps.
• • These models allow study of early lesions and progression.
• • Induced models:
• • Chemical induction (e.g., azoxymethane) combined with genetic mutations to accelerate tumorigenesis.
• • Orthotopic transplantation of gene-edited organoids into mice.

These models are essential for validating mechanisms and testing preventive strategies.

CRISPR-based gene editing enables the creation of isogenic cell lines with precise mutations in HMPS-related genes. For example:

• • TP53 knockout (TP53-/-) in HCT116 cells to study loss of tumor suppressor function.
• • KRAS G12D knock-in in DLD-1 cells to model activating mutations.
• • BMPR1A knockout in colorectal cell lines to mimic loss of BMP signaling.
• • GREM1 overexpression via CRISPRa (activation) or knock-in of a strong promoter.

These gene-edited models are commercially available from various sources, but it is important to select sequence-verified, clonally derived lines to ensure reproducibility. They are used to validate gene function, screen for drug sensitivity, and study resistance mechanisms. For instance, isogenic pairs differing only in a specific mutation allow direct comparison of phenotypic effects, reducing confounding factors.

Gene-edited cell lines are powerful tools for functional genomics. For HMPS, researchers can:

• • Knockout genes like BMPR1A or GREM1 to assess their role in cell proliferation, migration, and stemness.
• • Use knock-in mutations (e.g., KRAS G12D) to study oncogenic signaling.
• • Perform CRISPR screens to identify synthetic lethal partners or modifiers of drug response.

Example: A CRISPR screen in BMPR1A-knockout cells could identify genes that become essential when BMP signaling is lost, revealing new therapeutic targets.

Isogenic cell line pairs (e.g., wild-type vs. KRAS G12D knock-in) are used for high-throughput drug screening to identify compounds that selectively kill mutant cells. This approach helps in:

• • Identifying inhibitors of the MAPK pathway (e.g., MEK inhibitors) that are effective in KRAS-mutant backgrounds.
• • Studying resistance mechanisms by exposing cells to increasing drug concentrations and then sequencing to identify resistance mutations.
• • Testing combination therapies that target both BMP and Wnt pathways.

For example, a BMPR1A-knockout line could be used to screen for compounds that restore BMP signaling or inhibit downstream Wnt targets.

CRISPR-based synthetic lethality screens in HMPS models can uncover biomarkers for patient stratification. For instance:

• • In GREM1-overexpressing cells, knocking out genes involved in the BMP pathway may cause cell death, identifying potential biomarkers of sensitivity.
• • Gene-edited cells can be used to validate candidate biomarkers by correlating expression levels with drug response.
• • Transcriptomic and proteomic profiling of isogenic pairs can reveal differentially expressed genes that serve as diagnostic or prognostic markers.

These approaches accelerate the development of precision medicine strategies for HMPS.

The following table lists key public databases for HMPS research.